Journal of Medical Ethics 28 (1):20-23 (2002)

In this paper the need for valid evidence of the cost-effectiveness of treatments that have not been properly evaluated, yet are already available, albeit in short supply, are examined. Such treatments cannot be withdrawn, pending proper evaluation, nor can they be made more widely available until they have been shown to be cost-effective. As a solution to this impasse the argument put forward recently by Toroyan et al is discussed. They say that randomised controlled trials of such resources could be done but only if resources are randomly allocated independently of a research context. Relevant outcome data could then be collected for research, given this opportunity. We agree. We disagree with Toroyan et al on a number of points. First, they claim that no ethical issue relating to equipoise arises. We disagree and this disagreement depends on our showing that equipoise should be maintained in a relationship that they do not consider. Secondly, they say that consent to data collection is always needed. Again we disagree. Thirdly, they claim that the previous two issues are the only possible ethical issues that could arise. We argue, instead, that there is a further conflict of interests that has ethical import
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1136/jme.28.1.20
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 64,159
Through your library

References found in this work BETA

Add more references

Citations of this work BETA

Add more citations

Similar books and articles


Added to PP index

Total views
13 ( #749,004 of 2,454,913 )

Recent downloads (6 months)
1 ( #449,233 of 2,454,913 )

How can I increase my downloads?


My notes